Date:	_2022/8/15	
Your Name:	Wei Ma	
Manuscript Title:	PTS is activated by ATF4 and promotes LUAD development via the Wnt pathway	
Manuscript number	if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Natural Science Foundation of Shandong Province (No. ZR2020MH233)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
/	meetings and/or travel	XNotie	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
4.2			
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Plea	se summarize the above co	nflict of interest in the	following box:
V	Vei Ma reports funding support	t from the Natural Science	Foundation of Shandong Province (No. ZR2020MH233).
1			

Date	e:2022/8/1	.5	
You	r Name: Chao	Wang	
Mar	nuscript Title: PTS is act	tivated by ATF4 and promo	otes LUAD development via the Wnt pathway
Mar	nuscript number (if known):		
relate part to trelate	ted to the content of your r ies whose interests may be ansparency and does not n tionship/activity/interest, i following questions apply t	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so.
man	nuscript only.		
to th	• •	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is	- · · · · · · · · · · · · · · · · · · ·	d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
2	Cuanta an aantit f	Time frame: pas	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
2	in item #1 above).	V None	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events	V N			
6	Payment for expert	XNone			
	testimony				
7	Support for attending	X None			
′	meetings and/or travel	XNotie			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	X None			
11	Stock of Stock options				
12	Receipt of equipment,	X None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Dla	Please summarize the above conflict of interest in the following box:				
Pie	ase summarize the above co	milici of interest in the foll	owing box:		
	None				
'	NOTIC				
1					

Date	e:2022/8/1	.5	
You	r Name: Ruzhe	en Li	
Man	nuscript Title: PTS is act	tivated by ATF4 and prom	otes LUAD development via the Wnt pathway
Man	nuscript number (if known):		
relat part to tr relat	ted to the content of your r ies whose interests may be ansparency and does not n tionship/activity/interest, i	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current
man	uscript only.		
to the med	ne epidemiology of hyperte lication, even if that medica	nsion, you should declare ation is not mentioned in to port for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other items
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	·
		needed)	
		Time frame: Since the initial	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X None	
	,		
4	Consulting fees	X None	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events	V N			
6	Payment for expert	XNone			
	testimony				
7	Support for attending	X None			
′	meetings and/or travel	XNotie			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	X None			
11	Stock of Stock options				
12	Receipt of equipment,	X None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Dla	Please summarize the above conflict of interest in the following box:				
Pie	ase summarize the above co	milici of interest in the foll	owing box:		
	None				
'	NOTIC				
1					

Date	e:2022/8/1	.5	
	r Name: Zhaoh		
Mar	lanuscript Title: PTS is activated by ATF4 and promotes LUAD development via the Wnt pathway		
Mar	nuscript number (if known):		
rela part to ti rela	ted to the content of your n ies whose interests may be ransparency and does not n tionship/activity/interest, it	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do	
		o the author's relationship	s/activities/interests as they relate to the <u>current</u>
IIIai	nuscript only.		
to tl	• •	nsion, you should declare a	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.
	em #1 below, report all sup time frame for disclosure is	•	l in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	,
		needed)	
		Time frame: Since the initia	l planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
•		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
2	in item #1 above).	V None	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus, manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
_				
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or pending	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society, committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	X None		
12	materials, drugs, medical	XNotie		
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	ase summarize the above co	nflict of interest in the fol	lowing box:	
N	None			

Date	e:2022/8/1	ــــــــــــــــــــــــــــــــــــــ		
You	r Name: Yuan:	zhu Jiang		
Mar	nuscript Title: PTS is ac	ript Title: PTS is activated by ATF4 and promotes LUAD development via the Wnt pathway		
Mar	nuscript number (if known):	'		
rela part to t	ted to the content of your r ties whose interests may be	manuscript. "Related" mea affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.	
The			ps/activities/interests as they relate to the <u>current</u>	
to t		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.	
	em #1 below, report all sup time frame for disclosure is		d in this manuscript without time limit. For all other items	
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initia	al planning of the work	
1	All support for the present	XNone		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.) No time limit for this item.			
	No time limit for this item.			
		Timo from a	t 26 months	
2	Grants or contracts from	Time frame: pass	t 50 months	
۷	any entity (if not indicated	XNone		
	in item #1 above).			
3	Royalties or licenses	X None		
5	Noyalties of ficelises	XNOTIC		
4	Consulting fees	X None		

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus, manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
_				
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or pending	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society, committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	X None		
12	materials, drugs, medical	XNotie		
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	ase summarize the above co	nflict of interest in the fol	lowing box:	
N	None			

Dat	e:2022/8/1	.5	
	r Name: Xiang		
Maı	anuscript Title: PTS is activated by ATF4 and promotes LUAD development via the Wnt pathway		
Maı	nuscript number (if known):		
rela part to to rela	ted to the content of your r ties whose interests may be ransparency and does not n tionship/activity/interest, i	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
mar	nuscript only.		
to the med	he epidemiology of hyperte dication, even if that medica	nsion, you should declare a ation is not mentioned in the port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript. I in this manuscript without time limit. For all other items,
		Name all entities with	Constituent of Community
		whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	·
		needed)	
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
2	Country on continue to firm	Time frame: past	t 36 months
2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	X None	
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
4	Consulting fees	X None	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus, manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
_				_	
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or pending	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society, committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X None			
12	materials, drugs, medical	XNotie			
	writing, gifts or other			_	
	services				
13	Other financial or non-	XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				
N	lone				

Date: July 30, 2022 Your Name: Duilio Divisi

Manuscript Title: PTS is activated by ATF4 and promotes LUAD development via the Wnt pathway

Manuscript number (if known): //

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	None	
	testimony		
_			
7	Support for attending meetings and/or travel	None	
	meetings and/or traver		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
10	Advisory Board		
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
DI -	an aumamanina tha abassa sa	uflict of intovert in the fell	auding have
Pie	ase summarize the above co	nflict of interest in the foli	owing box:

U.O.C. CHIRURGIA TIDRACICA FOR DI DUMO DIVISI

Date: August 11 2022

Your Name: Enrico Capobianco

Manuscript Title: PTS is activated by ATF4 and promotes LUAD development via the Wnt pathway

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5 Payment o				
•	or honoraria for	None		
	resentations,			
speakers b				
	t writing or			
education				
Payment for		None		
testimony				
' Support fo	r attending	None		
	and/or travel			
J	,			
Patents pla	anned, issued or	None		
pending				
Participation	on on a Data	None		
	nitoring Board or			
Advisory B				
	o or fiduciary role	None		
		None		
	oard, society,			
	or advocacy			
	d or unpaid			
L1 Stock or st	ock options	None		
	equipment,	None		
	drugs, medical			
writing, gif	fts or other			
services				
13 Other fina	ncial or non-	None		
financial in	nterests			
lease summa	rize the above co	nflict of interest in the foll	owing hov:	
icase summa	TIZE CHE above co	inner of interest in the foil	owing box.	
I have no COI				
Thave no cor	•			
Please place an "X" next to the following statement to indicate your agreement:				
	n "X" next to the	tollowing statement to ind	licate your agreement:	
lease place a	. A next to the			
lease place a	A HEAT TO THE		, ,	
			ive not altered the wording of any of the questions	

Date	e:2022/8/1	.5	
You	r Name: Lin Zh	nang	
Mar	nuscript Title: PTS is ac	tivated by ATF4 and promo	tes LUAD development via the Wnt pathway
Mar	nuscript number (if known):		
rela part to ti rela	ted to the content of your r ies whose interests may be ransparency and does not n tionship/activity/interest, i	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of list a so.
	nuscript only.		
to the med	ne epidemiology of hyperte lication, even if that medica	nsion, you should declare a ation is not mentioned in the port for the work reported	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript. I in this manuscript without time limit. For all other items
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	,
		needed)	
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	XNone	
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus, manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
_				_	
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or pending	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society, committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X None			
12	materials, drugs, medical	XNotie			
	writing, gifts or other			_	
	services				
13	Other financial or non-	XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				
N	lone				

Date:	_2022/8/15
Your Name:	Wei Dong
Manuscript Title:	PTS is activated by ATF4 and promotes LUAD development via the Wnt pathway
Manuscript number (i	f known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _ National Natural Science Foundation of China (No. 81802282) Time frame: past	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

_					
5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus, manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
	,				
7	Support for attending	XNone			
	meetings and/or travel				
8	Patents planned, issued or	X None			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
11	group, paid or unpaid	V None			
11	Stock or stock options	XNone			
12	Receipt of equipment,	X None			
12	materials, drugs, medical	XNONC			
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Plea	ase summarize the above co	onflict of interest in the foll	owing box:		
V	Wei Dong reports funding support from the National Natural Science Foundation of China (No. 81802282).				